References

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

10.1016/j.jacc.2021.12.012 · 2022 · External reference

Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association

10.1161/cir.0000000000001052 · 2022 · External reference

Management of patients with heart failure and preserved ejection fraction

10.1136/heartjnl-2022-321097 · 2023 · External reference

Heart Failure With Reduced Ejection Fraction: A Review

10.1001/jama.2020.10262 · 2020 · External reference

Heart Failure With Preserved Ejection Fraction (HFpEF)

2024 · External reference

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

10.1056/nejmoa2030183 · 2021 · External reference

Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF

10.1016/j.jchf.2024.04.018 · 2024 · External reference

Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial

10.7326/m21-0651 · 2021 · External reference

Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF

10.1016/j.jchf.2023.05.026 · 2023 · External reference

Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure

10.1016/j.jacc.2023.02.022 · 2023 · External reference

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations

10.1136/bmj-2021-067975 · 2022 · External reference

A proportional hazards model for the subdistribution of a competing risk

1999 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Adherence to Methodological Standards in Research Using the National Inpatient Sample

10.1001/jama.2017.17653 · 2017 · External reference

Unresolved reference

External reference

Health Care Spending in the United States and Other High-Income Countries

10.1001/jama.2018.1150 · 2018 · External reference

Unresolved reference

External reference

US health spending trends by age and gender: selected years 2002-10

10.1377/hlthaff.2013.1224 · 2014 · External reference

Unresolved reference

External reference

Adjusting Health Expenditures for Inflation: A Review of Measures for Health Services Research in the United States

10.1111/1475-6773.12612 · 2018 · External reference

Unresolved reference

External reference

United States Life Tables, 2017

2019 · External reference

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine

10.1001/jama.2016.12195 · 2016 · External reference

10.1016/s0140-6736(24)00757-8

10.1016/s0140-6736(24)00757-8 · 2024 · External reference

Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review

10.1186/s12955-020-01407-y · 2020 · External reference

Acute and chronic impact of cardiovascular events on health state utilities

10.1186/s12913-015-0772-9 · 2015 · External reference

Modeling medical treatment using Markov decision processes

2005 · External reference

Multi-model Markov decision processes

2021 · External reference

Current recommendations on the estimation of transition probabilities in Markov cohort models for use in health care decision-making: a targeted literature review

10.2147/ceor.s135445 · 2017 · External reference

Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction

10.1001/jamacardio.2021.1437 · 2021 · External reference

Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction

10.1001/jamainternmed.2022.5010 · 2022 · External reference

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

10.1056/nejmoa2107038 · 2021 · External reference

Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction

10.1001/jamacardio.2023.0077 · 2023 · External reference